Healthcare / Medical DevicesStockholm
$0.25
-0.00 (-0.59%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-64.2M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$300M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-126.0%
↓Gross Margin
84.7%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.1%
FCF CAGR
—
FCF margin
-516.7%
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.4M · net income $-48.1M · FCF $-38.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.4M | $7.4M | $6.2M | $6.2M | $5.8M |
| Net Income | $-48.1M | $-48.1M | $-66.2M | $-77.8M | $-77.0M |
| EBITDA | $-44.6M | $-44.6M | $-62.8M | $-74.6M | $-73.8M |
| EPS | -0.04 | -0.04 | -0.07 | -0.16 | -0.31 |
| Gross Margin | 84.7% | 84.7% | 90.2% | 84.9% | 79.4% |
| Operating Margin | -652.2% | -652.2% | -1070.2% | -1242.6% | -1313.6% |
| Net Margin | -653.3% | -653.3% | -1067.2% | -1247.2% | -1322.3% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | — | 0.00 |
| Current Ratio | 5.72 | 5.72 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-38.0M | $-38.0M | $-64.2M | $-81.4M | $-75.0M |
| Returns | |||||
| ROE | -126.0% | -126.0% | -87.4% | -150.0% | -148.5% |
| Valuation | |||||
| P/B | 7.45 | 7.45 | 2.96 | 1.79 | 1.29 |
| Growth & Yield | |||||
| Revenue Growth | 18.7% | 18.7% | -0.6% | 7.2% | — |
| EPS Growth | 42.9% | 42.9% | 56.3% | 48.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.07 → -0.04
Residual
+2.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.